Nesvategrast (OTT166) in Diabetic Retinopathy (DR)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05409235 |
Recruitment Status :
Completed
First Posted : June 8, 2022
Last Update Posted : January 8, 2024
|
Sponsor:
OcuTerra Therapeutics, Inc.
Collaborator:
Parexel
Information provided by (Responsible Party):
OcuTerra Therapeutics, Inc.
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | December 29, 2023 |
Actual Study Completion Date : | December 29, 2023 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 |
April 29, 2024 |